SAN FRANCISCO and HOUSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Yingli Pharma US, Inc. (the “Company” or “Yingli”), a biotechnology company developing innovative small molecules, and The University of Texas MD Anderson Cancer Center today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.
Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of the European Hematology Association (EHA) being held June 9-17, 2021.
Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of the European Hematology Association (EHA) being held June 9-17, 2021.
Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of the European Hematology Association (EHA) being held June 9-17, 2021.
Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of the European Hematology Association (EHA) being held June 9-17, 2021.
SHANGHAI, March 31, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma) announced topline results of a Phase II registration study of linperlisib, a PI3K? inhibitor, for the treatment of relapsed/refractory follicular lymphoma (FL). Linperlisib is a potent and highly selective oral PI3K? inhibitor that was developed for potentially more efficacious with a potentially more manageable and differentiated safety profile from other PI3K? class agents. The topline results of this single-arm Phase II study (NCT04370405) showed that linperlisib treatment led to significant clinical improvement for the patients with relapsed/refractory FL.
SHANGHAI, March 31, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma) announced topline results of a Phase II registration study of linperlisib, a PI3K? inhibitor, for the treatment of relapsed/refractory follicular lymphoma (FL). Linperlisib is a potent and highly selective oral PI3K? inhibitor that was developed for potentially more efficacious with a potentially more manageable and differentiated safety profile from other PI3K? class agents. The topline results of this single-arm Phase II study (NCT04370405) showed that linperlisib treatment led to significant clinical improvement for the patients with relapsed/refractory FL.
SHANGHAI, March 31, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma) announced topline results of a Phase II registration study of linperlisib, a PI3K? inhibitor, for the treatment of relapsed/refractory follicular lymphoma (FL). Linperlisib is a potent and highly selective oral PI3K? inhibitor that was developed for potentially more efficacious with a potentially more manageable and differentiated safety profile from other PI3K? class agents. The topline results of this single-arm Phase II study (NCT04370405) showed that linperlisib treatment led to significant clinical improvement for the patients with relapsed/refractory FL.